When we were 10-12c, some were saying it should be around 30c...

When we were 10-12c, some were saying it should be around 30c before agreements compared with similar peers that don't even have FDA approvals yet.

I'm not really expecting much with this coming quarterly. Continued cash burn, but this time with progress towards sales, inventory, and future potential sales.

Agreements is what will light the fire under this stock. It will also make further CR less of a problem if the company knows they can expect future sales to offset any immediate need for extra cashflow to get inventory moving, e.g. using existing loans (not utilized) or new ones as a short term vehicle to profitability.

I have seen the worst stocks with worst risk keep flying on nothing. So for LDX to start a genuine re-rate based on finally making it to a point people thought it would be at 2.5 years ago i.e. FebriDx approval, is something that should be welcomed by all holders.

I'm looking forward to baby steps. Further sales of ViraDx and CLIA waiver for FebriDx would be a nice start, especially before the quarterly.